Kåre Schultz is a Danish business executive, born May 21, 1961, best known as the former President and CEO of Teva Pharmaceutical Industries (2017–2022/23) and prior CEO of H. Lundbeck. As of June 2026, publicly available estimates place his net worth in the range of roughly $28 million to $53 million, based primarily on documented equity holdings in publicly traded companies. The honest caveat: these figures are derived from SEC insider filings and reported share positions, not a full personal balance sheet, so they almost certainly undercount his total wealth.
Kåre Schultz Net Worth: Sources, Estimate, and How It’s Derived
Marcus Rothstein
7 Jun 2026
Which Kåre Schultz is this, and how to confirm
There is one Kåre Schultz who stands out clearly in public business records, and the identity trail is unusually well-documented. He is a Danish national, born May 21, 1961, who earned a cand.polit. degree from the University of Copenhagen in 1987. His spouse is Marianne Schultz. He has held CEO-level roles at two major pharmaceutical companies (Lundbeck and Teva) and currently serves on the boards of Azelis (as Chair), Hims & Hers Health, and SAS (as Chairman). SEC filings, including Form 4 disclosures signed under his name, SEC 8-K appointment filings from Hims & Hers identifying him as age 63 at the time of his July 2024 appointment, and Teva's DEF 14A proxy statements all consistently point to this single individual.
If you come across references to a Kåre Schultz in a different context, say, a Danish academic or a private-sector professional outside pharmaceuticals and life sciences, that is a different person. The Kåre Schultz documented in SEC filings, Azelis corporate governance pages, and SAS board announcements is definitively the one this profile covers. The age (born 1961), nationality (Danish), educational background (University of Copenhagen), and career timeline are the fastest disambiguation signals to check.
What 'net worth' means and how these estimates get built
Net worth, in the simplest sense, is total assets minus total liabilities. For a private individual like Schultz, nobody has access to his bank accounts, real estate portfolio, private investments, or personal liabilities. What financial aggregators and researchers like Benzinga, QuiverQuant, and GuruFocus actually do is something narrower: they pull SEC insider ownership filings, count the publicly reported shares held across named companies, multiply those by current market prices, and call it a net worth estimate. That is a useful starting point, but it is not the same thing as a full financial picture.
The components that feed a well-constructed estimate for an executive like Schultz include: disclosed equity holdings in public companies (from Form 4 filings and proxy statements), historical compensation as documented in DEF 14A filings (salary, bonus targets, and equity grant values), and directorship remuneration disclosed in annual reports like the Azelis Integrated Report. What stays invisible are private assets, real estate not disclosed in public filings, offshore structures, private equity stakes, and accumulated savings from decades of senior executive pay. This is why any published figure should be treated as a documented-equity floor, not a ceiling.
Career overview and the income signals that matter
Schultz's career is the kind of trajectory that generates substantial wealth quietly over time. He rose through senior finance and strategy roles at Novo Nordisk before becoming CFO and later COO there, then moved to CEO of H. Lundbeck, a Copenhagen-based pharmaceutical company. His most financially significant posting was as President and CEO of Teva Pharmaceutical Industries, one of the world's largest generic drug makers, from September 2017 through late 2022 (with his formal departure confirmed into 2023 per Azelis corporate records).
Teva's DEF 14A proxy filings document his compensation structure during that CEO tenure in specific terms: an annual base salary of $2 million, a target annual incentive of 140% of base salary (with a maximum of 200%), and a long-term equity incentive with a target grant-date fair value of $10 million, of which 70% was performance-based. Running the numbers on the target package alone, a single year at Teva represented roughly $14.8 million in targeted total direct compensation. Across a five-plus-year CEO run, even accounting for performance variability and equity vesting timelines, the cumulative compensation would be substantial. Additionally, a housing reimbursement was documented with specific exchange-rate assumptions (3.35 shekels per U.S. dollar for 2022 averages), which illustrates the international structure of his pay.
Since stepping down from the Teva CEO role, Schultz has transitioned into a portfolio of board chair and directorship positions. He joined Azelis (a specialty chemicals distributor listed on Euronext Brussels) as a non-executive director and Chair in 2024. He joined the Hims & Hers Health board in July 2024. And he serves as Chairman of the restructured SAS airline board, as confirmed in SAS corporate announcements. These roles carry director remuneration and equity grants rather than executive salary packages, so his active income is now considerably lower than during his Teva years, though the wealth accumulated during that period remains.
Business holdings, ownership, and what's actually documented
Three company relationships produce verifiable public holding data for Schultz as of mid-2026.
| Company | Role | Holding Evidence | Primary Public Source |
|---|---|---|---|
| Teva Pharmaceutical (TEVA) | Former President & CEO | Equity grants and ownership per DEF 14A filings; residual TEVA shares reported in insider aggregator data | SEC DEF 14A; Benzinga insider data |
| Hims & Hers Health (HIMS) | Board Director (from July 2024) | RSU grants per director compensation policy; Form 4 filings on file with SEC | SEC 8-K; Form 4 XML filing |
| Azelis Group (AZE:Euronext) | Non-Executive Chair (from 2024) | Share holdings per year-end table in Azelis Integrated Report; director remuneration in EUR disclosed | Azelis Integrated Report 2024 and 2025 PDFs |
| SAS | Board Chairman | Directorship confirmed in corporate announcement; compensation per board remuneration policy | SAS FY 2024 Annual Report; SAS board announcement PDF |
| IFF (International Flavors & Fragrances) | Prior directorship (referenced by Benzinga) | Shares cited as component of Benzinga's reported-share estimate | Benzinga insider trades page |
The Azelis Integrated Reports for 2024 and 2025 are particularly useful because they publish a table showing Kåre Schultz's remuneration in euros and his share holdings as of a specific date (December 1, 2025 in the 2025 report). This is one of the few non-SEC sources that directly names a holding quantity tied to a specific date, making it useful for triangulation. The Hims & Hers Form 4 filings, accessible through SEC EDGAR, document RSU grants and any subsequent transactions, and are updated within days of any insider activity.
The estimated net worth range, and why the numbers vary so much
Three aggregators have published estimates, and they land in noticeably different places. For more detail on the reported figures, see the overall schultz net worth range and how it’s derived from disclosed holdings. Benzinga, QuiverQuant, and GuruFocus each publish different ed schultz net worth style estimates based on overlapping but not identical filings published estimates. Benzinga estimates Schultz's net worth at approximately $28 million, based on reported shares across Teva, IFF, and Hims & Hers, with its estimate recalculated as of June 18, 2025. You may also see the same figures summarized in searches like alex schultz net worth Schultz's net worth. QuiverQuant puts the figure at at least $53.2 million, with an update timestamp that reflects current share pricing at the moment of page load, meaning the number shifts daily. GuruFocus also provides an insider-ownership-based figure, calculated from SEC ownership reports across named companies, though it frames the output around publicly traded equity positions rather than a comprehensive wealth figure.
The gap between $28 million and $53 million is not a sign that one source is wrong. It reflects genuine methodological differences: which companies' filings are included, how indirectly held shares (through entities or family trusts) are classified, whether shares that have vested and been sold are still counted, and how grant-date equity values are updated to current market prices. QuiverQuant's own page flags these limitations directly, noting that parsing errors, double-counting of indirectly owned shares, and filing classification issues can all affect the output.
A reasonable, defensible estimate for June 2026 sits in the $30 million to $55 million range for documented publicly traded equity. The lower bound is anchored by Benzinga's equity-only calculation; the upper bound reflects QuiverQuant's more expansive reading of insider filings. But given the scale of Schultz's executive compensation at Teva across five years (with annual target packages in the range of $14 to $15 million), his total personal wealth including private assets, real estate, and accumulated savings could plausibly be higher than either figure suggests. Treating $50 million as a reasonable midpoint estimate is defensible, with the acknowledgment that the true number remains private. Overall, this puts Kåre Schultz's donald schultz net worth estimate in the tens of millions, but it is still only based on documented public equity holdings.
How reliable is any of this, really
The core limitation is structural: there is no full-disclosure requirement for personal wealth for a private individual, even a public company director. If you are specifically looking for the latest estimate of Donald Schupak net worth, use the same SEC-filings-based approach and then compare multiple aggregators to see where they diverge. SEC Form 4 filings are required to report changes in beneficial ownership of public company securities, but they do not capture private company stakes, real estate, cash, debt, or any assets outside SEC-regulated holdings. This means every published estimate is a partial picture.
Currency timing is another factor. Teva's DEF 14A filings include shekel-to-dollar conversions based on average annual exchange rates (for example, 3.35 shekels per dollar for 2022). Azelis reports compensation in euros. If you are trying to build an aggregate USD-denominated net worth figure, exchange rate assumptions as of different dates will produce different totals. Benzinga's figure was recalculated in June 2025, not June 2026, so share price movements since then affect its accuracy today.
Equity grant structures also create timing distortions. Teva's DEF 14A disclosed grant-date fair values for long-term equity incentives. Aggregators who pull those values and apply current TEVA share prices to the implied share counts will get a different number than the original grant-date fair value, and the direction of that difference depends entirely on how TEVA stock has performed since the grant. For a company like Teva, which has been through significant financial turbulence, this is a material source of uncertainty.
How to verify or update this yourself today
If you want to build your own current-as-of-today picture, here is the practical sequence to follow.
- Start with SEC EDGAR full-text search (efts.sec.gov) and search for 'Kare Schultz' as a reporting person. Pull all Form 4 filings. Each one documents a transaction in a public company security and shows his current holdings after each trade. This is the most directly verifiable data point available.
- Pull Teva's DEF 14A from the most recent available fiscal year covering Schultz's CEO tenure (look for filings from fiscal years 2018 through 2022). The executive compensation tables disclose salary, bonus, and equity grant fair values in exact dollar figures.
- Access the Hims & Hers DEF 14A (April 26, 2024, accession 0001773751-24-000110 on EDGAR) for the director compensation policy. Cross-reference with any Form 4 filings showing RSU grants or sales.
- Download the Azelis Integrated Report 2025 PDF (published April 2025 via the Azelis investor relations page). Look for the director remuneration and share-holding table, which shows Schultz's shares held as of December 1, 2025 and his EUR remuneration for the year.
- Check SAS's FY 2024 Annual and Sustainability Report for board remuneration details tied to Schultz's Chair role.
- Apply current market prices to the share quantities you have identified across all companies (TEVA, HIMS, AZE on Euronext, and any others). Sum the resulting values to get an updated equity-based estimate.
- Cross-check against QuiverQuant and Benzinga for a sanity check, but use them as a starting reference, not a final answer. Note the timestamp on any third-party estimate and assume it is stale if it is more than a few weeks old given share price sensitivity.
One thing worth keeping in mind: Schultz's most wealth-generative years were the Teva CEO years from 2017 to 2022. His current role as a multi-company board chair generates director fees and equity grants that are meaningful but a fraction of executive CEO compensation. The wealth you are trying to estimate is mostly accumulated, not actively growing at the same rate it was during the Teva period. That context matters when reading any estimate, because the trajectory has shifted from accumulation to preservation and portfolio management.
For readers exploring the broader landscape of executive wealth in this surname category, Schultz is one of the more thoroughly documented profiles in this space, given his roles at publicly listed companies with mandatory SEC and Euronext disclosures. Other executives sharing the Schultz surname present varying degrees of documentation depending on whether their wealth is tied to public or private holdings, which shapes how precisely any estimate can be anchored.
FAQ
Why can Kåre Schultz’s net worth estimates swing so much between $28 million and $53 million?
Most of the spread comes from which public-company holdings are included, how “beneficial ownership” is interpreted (direct vs indirect holdings), and whether sold or vested shares are still counted. Different aggregators also revalue equity using different share prices and different “as-of” dates, so the same underlying filings can produce different totals.
Do SEC Form 4 filings capture Kåre Schultz’s full wealth?
No. Form 4 reports changes in beneficial ownership of public securities, but it excludes private company stakes, real estate, cash, loans, and many kinds of private investment. That means any “net worth” number based on SEC filings is best treated as an equity-only floor, not a full balance sheet.
How should I interpret estimates that are described as “updated daily” or “as of today”?
Those figures usually take an insider-owned share count from filings and then multiply it by the current market price. That produces day-to-day movement even if the share count did not change. If you want consistency, compare estimates using the same valuation date or the same market-price source.
What’s the biggest mistake people make when comparing different net worth sites?
Comparing totals without checking what each site counts. For example, some approaches include only directly held shares, while others attempt to parse indirectly held shares through entities or trusts, which can also introduce classification errors or double-counting.
If Teva stock price moved a lot after his grants, will grant-date fair value equal today’s implied value?
Not necessarily. DEF 14A often reports grant-date fair values, while later “net worth” estimates commonly revalue the implied share holdings using current prices. Depending on whether the stock rose or fell since the grant, the recalculated value can be substantially higher or lower than the grant-date figure.
How do currency conversions affect a Kåre Schultz net worth calculation?
They can affect inputs like pay components expressed in shekels and compensation reported in euros, especially when a site tries to translate historic or target equity values into USD. If two sites use different exchange-rate dates, the resulting totals can diverge even if they start from the same filings.
Are board chair and director roles likely to change his net worth much going forward?
They can add meaningful director remuneration and occasional equity, but they usually do not match the scale of CEO compensation. The article’s main point holds, most wealth accumulation likely occurred during earlier executive years, while later roles tend to be more about preserving and diversifying what he already built.
Could there be another Kåre Schultz with a different net worth?
Yes, name duplication is possible. The reliable disambiguation signals are his birth year (1961), Danish nationality, and the specific set of public-company roles and filings tied to that exact individual. If a claim does not match those identifiers, treat it as potentially a different person.
What would a “good enough” DIY check look like if I want to verify the estimate?
Start by pulling the relevant Form 4 and proxy disclosures for the specific companies connected to his board and executive history, extract share counts and any RSU or option activity, then revalue using a single clearly stated valuation date and currency convention. Also note whether the listing includes only current holdings or also transient positions that later sold.
Why might one aggregator show a much higher figure than another even if both use the same SEC filings?
They may interpret indirect ownership differently, include or exclude certain subsidiaries or reporting entities, or apply different rules for what counts as “beneficially owned.” Some also use parsing logic that can misclassify entities or miss filings, which can push the estimate upward or downward.
Does any estimate account for wealth in private assets like real estate?
Usually not. Unless a private-asset disclosure exists in a filing or report, most published “net worth” numbers remain equity-focused. Real estate, private investment vehicles, and personal debts are typically invisible to SEC-based methods, so the true total can be higher or lower than the public-equity total.
Citations
There is a Danish business executive named Kåre Schultz, born May 21, 1961, with a public bio describing he served as CEO of Teva Pharmaceutical Industries (2017–2022) and previously CEO of Lundbeck.
Kåre Schultz (Wikipedia) - https://en.wikipedia.org/wiki/K%C3%A5re_Schultz
Azelis’ leadership/corporate governance page identifies Kåre Schultz as Chair of the Board of Directors and states he joined Azelis as a non-executive director in 2024; it also gives his most recent roles as President/CEO of Teva (2017–retired in 2023) and prior CEO of H. Lundbeck.
Leadership & Corporate Governance | Azelis - https://www.azelis.com/en/about-azelis/leadership
Hims & Hers’ investor relations press release (dated July 22, 2024) identifies Kåre Schultz as joining the company’s Board of Directors and links him to his prior executive leadership at Teva and Lundbeck.
Pharmaceutical Industry Chief Kåre Schultz Joins Hims & Hers Board (Hims & Hers IR) - https://investors.hims.com/news/news-details/2024/Pharmaceutical-Industry-Chief-Kre-Schultz-Joins-Hims--Hers-Board/default.aspx
The Wikipedia profile distinguishes this individual by naming his spouse (Marianne Schultz) and education (University of Copenhagen cand.polit. degree in 1987).
Kåre Schultz (Wikipedia) - https://en.wikipedia.org/wiki/K%C3%A5re_Schultz
Teva’s 2023 DEF 14A discloses Kåre Schultz’s employment terms during his CEO period, including annual base salary of $2 million and a target annual incentive opportunity of 140% of base salary (200% max), plus long-term equity incentive target grant date fair value totaling $10 million (70% performance-based).
DEF 14A (Teva Pharmaceutical Industries Ltd.) — compensation terms for Kåre Schultz - https://www.sec.gov/Archives/edgar/data/818686/000119312523106453/d468881ddef14a.htm
Teva DEF 14A filings also describe how Schultz’s compensation was structured to align incentives with performance and to build ownership in Teva upon sustained shareholder value (including equity/ownership components).
DEF 14A (Teva Pharmaceutical Industries Ltd.) - https://www.sec.gov/Archives/edgar/data/818686/000119312524097745/d11454ddef14a.htm
Hims & Hers filed an 8-K (July 16, 2024) stating Kåre Schultz (age 63) was appointed to its Board and that his compensation would follow the company’s director compensation section in the April 26, 2024 proxy statement.
Hims & Hers Health, Inc. — Appointment of Director (SEC 8-K filing) - https://www.sec.gov/Archives/edgar/data/1773751/000177375124000230/hims-20240716.htm
Hims & Hers’ April 26, 2024 definitive proxy (DEF 14A, accession listed on the SEC index page) is the SEC source location for director compensation and details used by compensation aggregators.
EDGAR Filing Documents for 0001773751-24-000110 (Hims & Hers DEF 14A index) - https://www.sec.gov/Archives/edgar/data/1773751/0001773751-24-000110-index.html
Teva’s SEC-linked exhibit page references the company’s communication/announcement of appointing Kåre Schultz as President and CEO (ties the name to the executive role in filings).
Teva Names Kåre Schultz as President and Chief Executive -- Update (SEC exhibit page) - https://www.sec.gov/Archives/edgar/data/818686/000089882217000138/exhibit.htm
Teva USA press release announcing Kåre Schultz as President and CEO provides a direct, company-published attribution to this individual for the CEO role at Teva.
Teva Announces Kåre Schultz as President and Chief Executive Officer (Teva USA PR) - https://www.tevausa.com/news-and-media/press-releases/teva-names-kare-schultz-as-president-and-chief-executive-officer/
Teva’s filing explicitly states Schultz “was not entitled to any compensation” in his capacity as a member of the Board/committees (distinguishing executive employment pay from director compensation).
DEF 14A (Teva Pharmaceutical Industries Ltd.) — director vs executive compensation note - https://www.sec.gov/Archives/edgar/data/818686/000119312523106453/d468881ddef14a.htm
SAS’ FY 2024 annual and sustainability report (PDF) identifies Kåre Schultz as Board Chairman, reinforcing his post-Teva public board leadership identity.
SAS Annual and Sustainability Report FY 2024 - https://www.sasgroup.net/files/documents/financial-reports/2024/SAS-Annual-and-Sustainability-Report-FY-2024.pdf
SAS’ announcement PDF states Kåre Schultz is designated as Chairman of the Board for the reorganized company (board identity confirmation in corporate communications).
SAS announces designated Board of Directors (PDF) - https://www.sasgroup.net/files/Main/290/4029977/sas-announces-designated-board-of-directors.pdf
Wikipedia states Schultz was CEO of Teva between September 2017 and December 2022 and had earlier leadership at Novo Nordisk and Lundbeck.
Kåre Schultz (Wikipedia) - https://en.wikipedia.org/wiki/K%C3%A5re_Schultz
SEC filing provides age (63) at appointment to Hims & Hers board—useful for disambiguation versus other people with similar names.
Hims & Hers Health, Inc. — Appointment of Director (SEC 8-K filing) - https://www.sec.gov/Archives/edgar/data/1773751/000177375124000230/hims-20240716.htm
Teva’s DEF 14A includes specific compensation components (salary, target incentive, long-term equity fair value, relocation/housing reimbursement limits) that can serve as the income signal basis for estimating net worth lower bounds (cash/wealth accumulation).
DEF 14A (Teva Pharmaceutical Industries Ltd.) — compensation components - https://www.sec.gov/Archives/edgar/data/818686/000119312523106453/d468881ddef14a.htm
Teva’s DEF 14A material discusses governance/compensation alignment approach and provides evidence that equity ownership incentives were part of Schultz’s pay package during his tenure.
DEF 14A (Teva Pharmaceutical Industries Ltd.) - https://www.sec.gov/Archives/edgar/data/818686/000119312524097745/d11454ddef14a.htm
A Form 4-related page indicates insider activity/RSU grants for Kåre Schultz as a Hims & Hers director (evidence of direct equity holdings and director equity compensation).
HIMS insider trading activity — Form 4 (StockTitan) - https://stocktitan.net/sec-filings/HIMS/form-4-hims-hers-health-inc-insider-trading-activity-0742f51d49d1.html
SEC Form 4 filing XML shows reporting person signatures “for Kare Schultz,” demonstrating that the named individual is a filer on public insider transaction reports (disambiguation and holding/transaction source).
SEC Form 4 XML (Hims & Hers reporting person Kare Schultz) - https://www.sec.gov/Archives/edgar/data/1773751/000177375125000299/xslF345X05/wk-form4_1758151469.xml
Teva corporate press materials confirm Schultz’s CEO appointment with company-issued context suitable as a career milestone source.
Teva Announces Kåre Schultz as President and Chief Executive Officer (Teva USA PR) - https://www.tevausa.com/news-and-media/press-releases/teva-names-kare-schultz-as-president-and-chief-executive-officer/
Teva’s DEF 14A contains a detailed executive compensation section for Schultz with the disclosed value amounts and exchange-rate assumptions for housing reimbursement (example: $11,933 using a 2022 average monthly exchange rate of 3.35 shekels per U.S. dollar).
DEF 14A (Teva Pharmaceutical Industries Ltd.) — housing reimbursement conversion note - https://www.sec.gov/Archives/edgar/data/818686/000119312523106453/d468881ddef14a.htm
SEC-linked material for Teva CEO appointment connects Schultz’s name to the CEO role in SEC context (helps distinguish the identity from similarly named individuals).
Teva Names Kåre Schultz as President and Chief Executive -- Update (SEC exhibit page) - https://www.sec.gov/Archives/edgar/data/818686/000089882217000138/exhibit.htm
Azelis provides “Integrated Report 2024” via its reports page; this is the corporate source location where director remuneration and share-holding tables are published.
2024 reports and presentations | Azelis - https://www.azelis.com/en/2024reportsandpresentations
Azelis’ Euronext listing for the AGM convening notice references Schultz as a director for a term and states remuneration is per the company’s remuneration policy; it also points to CV/information on mandates as supporting documentation for identity.
Azelis Group NV: Ordinary and Extraordinary General Shareholders' Meeting Convening Notice - https://live.euronext.com/en/products/equities/company-news/2024-05-08-azelis-group-nv-ordinary-and-extraordinary-general
Azelis Integrated Report 2024 (published April 2025 as an RNS PDF) lists Kåre Schultz as an independent non-executive director (chair) with remuneration in EUR and an explicit share-holding number (example: table shows “Kåre Schultz … Remuneration (in €) …” and includes committee/tenure context).
Azelis Integrated Report 2024 (PDF via financialreports.eu CDN) - https://cdn.financialreports.eu/financialreports/media/filings/3909/2025/RNS/3909_rns_2025-04-07_1ece6bf3-f004-4e0b-9381-0359e19f555c.pdf
Azelis Integrated Report 2025 PDF includes a table with “Remuneration (in €)” and “Shares held per 1/12/2025” for Kåre Schultz (chair), providing time-specific direct share-holding evidence tied to his identity.
Azelis Integrated Report 2025 (PDF) - https://a.storyblok.com/f/329380/x/b88fba9c03/azelis-group-nv-integrated-report-2025.pdf
Teva executive appointment material is one of the core publicly documented identity-to-role links used to avoid name confusion.
Teva Names Kåre Schultz as President and Chief Executive -- Update (SEC exhibit page) - https://www.sec.gov/Archives/edgar/data/818686/000089882217000138/exhibit.htm
Benzinga’s net worth page estimates “Kare Schultz’s net worth” at $28 million, stating its estimate is based on reported shares across multiple companies (it cites TEVA, IFF, and Hims & Hers as components).
Kare Schultz Net Worth - Insider Trades and Bio as of Mar 26, 2026 (Benzinga) - https://www.benzinga.com/sec/insider-trades/0001724567/kare-schultz
QuiverQuant estimates Kare Schultz net worth at least $53.2 million (as of its page’s “today” timestamp) and attributes it to estimated holdings including TEVA stock shares (page indicates an estimated number of TEVA shares and resulting value).
Kare Schultz Net Worth (2026) (QuiverQuant) - https://www.quiverquant.com/insiders/1724567/Schultz-Kare
GuruFocus provides an insider ownership/“net worth” style page for Kare Schultz based on ownership reports from SEC filings; it explicitly frames its computation around SEC-reported insider holdings and associated company ownership.
Kare Schultz Net Worth and Insider Trading (GuruFocus) - https://www.gurufocus.com/insider/104232/kare-schultz
QuiverQuant also notes limitations (e.g., possible inaccuracies related to privately holding filing errors, parsing errors, or double-counting).
Kare Schultz Net Worth (2026) (QuiverQuant) - https://www.quiverquant.com/insiders/1724567/Schultz-Kare
Benzinga’s page states its estimate was recalculated on Jun 18, 2025, and provides a figure ($28 million) plus the underlying premise that it is derived from “reported shares across multiple companies.”
Kare Schultz Net Worth - Insider Trades and Bio as of Mar 26, 2026 (Benzinga) - https://www.benzinga.com/sec/insider-trades/0001724567/kare-schultz
QuiverQuant’s page indicates a “last updated” time (page shows update as within hours), implying its net-worth estimate is sensitive to current share prices and recent trades.
Kare Schultz Net Worth (2026) (QuiverQuant) - https://www.quiverquant.com/insiders/1724567/Schultz-Kare
Teva’s DEF 14A provides specific executive pay information (base salary and incentive/equity target values), which helps explain why publicly documented income signals can be large even if net worth estimates still vary due to private assets/unreported holdings.
DEF 14A (Teva Pharmaceutical Industries Ltd.) — Kåre Schultz compensation - https://www.sec.gov/Archives/edgar/data/818686/000119312523106453/d468881ddef14a.htm
Teva’s filing also provides post-CEO structure (e.g., notes he was not entitled to compensation in board capacity), which affects net worth modeling because director compensation may be much smaller than executive cash/equity while he was CEO.
DEF 14A (Teva Pharmaceutical Industries Ltd.) — board vs executive compensation note - https://www.sec.gov/Archives/edgar/data/818686/000119312523106453/d468881ddef14a.htm
Hims & Hers SEC filing points to the proxy statement as the source for director compensation policies, which affects the observable cash-equity compensation component (but not private asset wealth).
Hims & Hers Health, Inc. — Appointment of Director (SEC 8-K filing) - https://www.sec.gov/Archives/edgar/data/1773751/000177375124000230/hims-20240716.htm
The SEC record confirms the reporting relationship and age at appointment, but it does not disclose full personal assets; that limitation is an important factor in why net worth websites disagree.
Hims & Hers Health, Inc. — Appointment of Director (SEC 8-K filing) - https://www.sec.gov/Archives/edgar/data/1773751/000177375124000230/hims-20240716.htm
QuiverQuant explicitly highlights methodological/data quality weaknesses that can lead to discrepancies in net worth estimates (e.g., filing/parsing errors and inaccurate classification of indirectly owned shares).
Kare Schultz Net Worth (2026) (QuiverQuant) - https://www.quiverquant.com/insiders/1724567/Schultz-Kare
Benzinga’s net worth methodology is framed around reported insider shares across multiple companies; this can undercount wealth held outside those reporting streams (private businesses, real estate not disclosed as holdings, offshore structures).
Kare Schultz Net Worth - Insider Trades and Bio as of Mar 26, 2026 (Benzinga) - https://www.benzinga.com/sec/insider-trades/0001724567/kare-schultz
For currency/valuation assumptions: Teva’s DEF 14A includes exchange-rate conversion for housing reimbursement, illustrating that filings may involve currency conversions and thus create timing/assumption differences when projecting values to “as of” dates.
DEF 14A (Teva Pharmaceutical Industries Ltd.) — housing reimbursement conversion note - https://www.sec.gov/Archives/edgar/data/818686/000119312523106453/d468881ddef14a.htm
Teva’s DEF 14A establishes that executive pay includes equity with fair-value and vesting structures; net worth sites may value equity using current market prices, while filings provide grant-date fair values—another source of disagreement.
DEF 14A (Teva Pharmaceutical Industries Ltd.) — compensation structure - https://www.sec.gov/Archives/edgar/data/818686/000119312523106453/d468881ddef14a.htm
GuruFocus’ approach is based on SEC insider ownership reports (public filings) rather than full balance-sheet disclosure, which can produce a partial net worth figure focusing mainly on publicly-traded equity positions.
Kare Schultz Net Worth and Insider Trading (GuruFocus) - https://www.gurufocus.com/insider/104232/kare-schultz
SEC Form 4 filings provide the most directly verifiable “as reported” evidence of changes in publicly-traded holdings for Kåre Schultz (useful for updating net worth estimates based on current share prices).
SEC Form 4 XML (Hims & Hers reporting person Kare Schultz) - https://www.sec.gov/Archives/edgar/data/1773751/000177375125000299/xslF345X05/wk-form4_1758151469.xml
Teva DEF 14A is a primary SEC source location for executive compensation and equity incentive details that readers can use as an income/wealth accumulation signal for modeling.
DEF 14A (Teva Pharmaceutical Industries Ltd.) — Kåre Schultz compensation - https://www.sec.gov/Archives/edgar/data/818686/000119312523106453/d468881ddef14a.htm
The SEC EDGAR index page for Hims & Hers’ DEF 14A (April 26, 2024) is a precise location readers can use to extract Kåre Schultz director compensation and related equity award mechanics.
EDGAR Filing Documents for 0001773751-24-000110 (Hims & Hers DEF 14A index) - https://www.sec.gov/Archives/edgar/data/1773751/0001773751-24-000110-index.html
Azelis’ reports page is an authoritative starting point to retrieve the Integrated Report PDF(s) that show director share holdings and remuneration (used to update non-US asset signals).
2024 reports and presentations | Azelis - https://www.azelis.com/en/2024reportsandpresentations
Euronext company-news pages for Azelis provide the convening notice and links to director CV/remuneration policy and terms—helpful for verifying directorship identity and tenure.
Azelis Group NV: Ordinary and Extraordinary General Shareholders' Meeting Convening Notice - https://live.euronext.com/en/products/equities/company-news/2024-05-08-azelis-group-nv-ordinary-and-extraordinary-general
SAS’ corporate announcement PDF is a primary corporate source to confirm Kåre Schultz’s board chair role and date-specific identity context.
SAS announces designated Board of Directors (PDF) - https://www.sasgroup.net/files/Main/290/4029977/sas-announces-designated-board-of-directors.pdf
Benzinga provides a specific net worth figure ($28 million) and indicates the estimate recalculation date (Jun 18, 2025), which readers can compare against updated share prices and holdings to triangulate a June 2026 range.
Kare Schultz Net Worth - Insider Trades and Bio as of Mar 26, 2026 (Benzinga) - https://www.benzinga.com/sec/insider-trades/0001724567/kare-schultz
QuiverQuant provides an alternate net worth figure (at least $53.2 million) with a very recent update timestamp, implying sensitivity to current market pricing and any updated share holdings in filings.
Kare Schultz Net Worth (2026) (QuiverQuant) - https://www.quiverquant.com/insiders/1724567/Schultz-Kare
GuruFocus provides a third net-worth/insider-ownership basis tied to SEC ownership reports across named companies, offering a different slice of publicly traded equity holdings.
Kare Schultz Net Worth and Insider Trading (GuruFocus) - https://www.gurufocus.com/insider/104232/kare-schultz
Next Article
Don Schultz Songwriter Net Worth: How to Verify It
Learn how to verify Don Schultz songwriter net worth using credits, royalties, and reputable financial sources, not gues
